ECSP21060962A - Composiciones farmacéuticas que comprenden meloxicam - Google Patents

Composiciones farmacéuticas que comprenden meloxicam

Info

Publication number
ECSP21060962A
ECSP21060962A ECSENADI202160962A ECDI202160962A ECSP21060962A EC SP21060962 A ECSP21060962 A EC SP21060962A EC SENADI202160962 A ECSENADI202160962 A EC SENADI202160962A EC DI202160962 A ECDI202160962 A EC DI202160962A EC SP21060962 A ECSP21060962 A EC SP21060962A
Authority
EC
Ecuador
Prior art keywords
meloxicam
migraine
rizatriptan
pain
administered
Prior art date
Application number
ECSENADI202160962A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71947112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21060962(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of ECSP21060962A publication Critical patent/ECSP21060962A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Se describe en la presente composiciones que comprenden un NSAID como meloxicam y/o rizatriptan en combinación con una ciclodextrina y/o un carbonato o un bicarbonato. Estas composiciones pueden ser oralmente administradas, por ejemplo, para mejorar la biodisponibilidad o farmacocinéticas del NSAID para el tratamiento de dolor como migraña, artritis, y otras afecciones. También se describen aquí métodos para tratar el dolor, como migraña, que comprenden administrar meloxicam y rizatriptan a un ser humano que sufre de dolor, como migraña. Para la migraña, estos métodos pueden ser particularmente útiles cuando el meloxicam y el rizatriptan son administrados mientras el ser humano está sufriendo de un ataque agudo de dolor de migraña o aura de migraña. En algunas modalidades, la combinación de meloxicam y rizatriptan pueden ser administrados en una forma que resulta en una Tmax de meloxicam de 3 horas o menos.
ECSENADI202160962A 2019-02-06 2021-08-17 Composiciones farmacéuticas que comprenden meloxicam ECSP21060962A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962802198P 2019-02-06 2019-02-06
US201962803756P 2019-02-11 2019-02-11
US201962835613P 2019-04-18 2019-04-18
US201962846311P 2019-05-10 2019-05-10
US201962860705P 2019-06-12 2019-06-12
US201962895933P 2019-09-04 2019-09-04
US201962895956P 2019-09-04 2019-09-04
US201962955905P 2019-12-31 2019-12-31

Publications (1)

Publication Number Publication Date
ECSP21060962A true ECSP21060962A (es) 2021-11-30

Family

ID=71947112

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202160962A ECSP21060962A (es) 2019-02-06 2021-08-17 Composiciones farmacéuticas que comprenden meloxicam

Country Status (19)

Country Link
EP (1) EP3920909A4 (es)
JP (5) JP7237386B2 (es)
KR (2) KR20210118880A (es)
CN (1) CN113423397A (es)
AU (3) AU2020218253B2 (es)
BR (1) BR112021015467A2 (es)
CA (2) CA3213549A1 (es)
CL (1) CL2021002070A1 (es)
CO (1) CO2021010380A2 (es)
CR (1) CR20210420A (es)
EC (1) ECSP21060962A (es)
IL (1) IL285389A (es)
MA (1) MA54904A (es)
MX (2) MX2021009435A (es)
MY (1) MY198967A (es)
NZ (1) NZ778435A (es)
PE (1) PE20212157A1 (es)
SG (1) SG11202107926XA (es)
WO (1) WO2020163620A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230125826A (ko) * 2020-12-31 2023-08-29 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
KR20260074736A (ko) * 2023-09-18 2026-05-26 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234324T3 (es) * 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
WO2004089365A1 (en) 2003-04-11 2004-10-21 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
BRPI0410807A (pt) 2003-06-06 2006-06-27 Glaxo Group Ltd composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica
EP3216445A1 (en) 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
PL3100728T3 (pl) * 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
SG10202010157VA (en) * 2015-02-10 2020-11-27 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
SMT202600087T1 (it) * 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
US10471014B2 (en) * 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
DK3565550T3 (da) * 2017-01-04 2021-01-18 Axsome Therapeutics Inc Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
KR102583443B1 (ko) * 2017-05-10 2023-09-26 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물

Also Published As

Publication number Publication date
JP2022519670A (ja) 2022-03-24
JP2023062144A (ja) 2023-05-02
MA54904A (fr) 2021-12-15
BR112021015467A2 (pt) 2021-10-05
JP7420990B2 (ja) 2024-01-23
JP7237386B2 (ja) 2023-03-13
EP3920909A1 (en) 2021-12-15
CR20210420A (es) 2021-12-22
MX2021009435A (es) 2021-09-10
AU2020218253A1 (en) 2021-08-12
JP7862619B2 (ja) 2026-05-19
JP2026116506A (ja) 2026-07-09
JP2024026732A (ja) 2024-02-28
CA3128940C (en) 2023-11-07
CN113423397A (zh) 2021-09-21
PE20212157A1 (es) 2021-11-09
NZ778435A (en) 2024-12-20
CA3213549A1 (en) 2020-08-13
SG11202107926XA (en) 2021-08-30
KR20210118880A (ko) 2021-10-01
IL285389A (en) 2021-09-30
AU2023202545A1 (en) 2023-05-18
MY198967A (en) 2023-10-05
MX2026005800A (es) 2026-06-01
KR20260066814A (ko) 2026-05-12
WO2020163620A1 (en) 2020-08-13
CA3128940A1 (en) 2020-08-13
AU2020218253B2 (en) 2023-02-23
AU2025230695A1 (en) 2025-10-02
CO2021010380A2 (es) 2021-09-30
JP7620125B2 (ja) 2025-01-22
EP3920909A4 (en) 2022-11-30
CL2021002070A1 (es) 2022-04-01
JP2025061137A (ja) 2025-04-10
AU2023202545B2 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
MX2021014509A (es) Composiciones farmaceuticas que comprenden meloxicam.
MX2024005716A (es) Composiciones farmaceuticas que comprenden meloxicam.
MX2022000143A (es) Metodos novedosos.
JOP20210050A1 (ar) معدلات تعبير pnpla3
JP2017149726A5 (es)
CO2020004034A2 (es) Métodos para el tratamiento de distrofia muscular
ECSP19014247A (es) Formas de dosificación para tratar y prevenir trastornos del sueño
CL2021002070A1 (es) Composiciones farmacéuticas que comprenden meloxicam.
EA200701195A1 (ru) Содержащие цефалоспорин композиции с наночастицами и с контролируемым высвобождением
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
EA201692392A1 (ru) Новая лекарственная форма мелоксикама
MX2020010417A (es) Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret.
JOP20200291A1 (ar) معدلات التعبير عن apol1
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
PH12019500349A1 (en) Diacylglycerol acyltransferase 2 inhibitors
BR112019009726A2 (pt) terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica
CO2021007006A2 (es) Moduladores de la expresión de irf5
BR122021012549B8 (pt) Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
MX2020003660A (es) Derivados de acido gluconico para ser usados en el tratamiento y/o prevencion de infecciones microbianas.
CO2021001528A2 (es) Combinación farmacéutica sinérgica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona
MX2018015208A (es) Andrografolido para tratar formas progresivas de esclerosis multiple.